These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33131892)

  • 61. Case Report: A Case Report of a Histological Transformation of
    Zhang Y; Qin Y; Xu H; Yao Q; Gao Y; Feng Y; Ren J
    Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
    Wang H; Wang Y; Zhang H; Han Y; Li Q; Ye Z
    Clin Radiol; 2020 Jul; 75(7):562.e21-562.e29. PubMed ID: 32307109
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements.
    Li S; Cao L; Wang X; Wang F; Wang L; Jiang R
    Med Sci Monit; 2019 Jan; 25():675-690. PubMed ID: 30673691
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
    Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
    Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies.
    Tantraworasin A; Lertprasertsuke N; Kongkarnka S; Euathrongchit J; Wannasopha Y; Saeteng S
    Asian Pac J Cancer Prev; 2014; 15(7):3057-63. PubMed ID: 24815447
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
    Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
    J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
    J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
    Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
    Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
    Pacheco JM; Gao D; Smith D; Purcell T; Hancock M; Bunn P; Robin T; Liu A; Karam S; Gaspar L; Kavanagh B; Rusthoven C; Aisner D; Doebele R; Camidge DR
    J Thorac Oncol; 2019 Apr; 14(4):691-700. PubMed ID: 30599201
    [TBL] [Abstract][Full Text] [Related]  

  • 74. ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".
    Mengoli MC; Bertolini F; Maur M; Barbieri F; Longo L; Gasparri P; Tiseo M; Rossi G
    Pathologica; 2017 Dec; 109(4):408-411. PubMed ID: 29449735
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis.
    Connolly JG; Scarpa JR; Gupta HV; Tan KS; Mastrogiacomo B; Dycoco J; Caso R; Jones GD; Sanchez-Vega F; Adusumilli PS; Rocco G; Isbell JM; Bott MJ; Irie T; McCormick PJ; Fischer GW; Jones DR; Mincer JS
    Br J Anaesth; 2021 Sep; 127(3):e82-e85. PubMed ID: 34272058
    [No Abstract]   [Full Text] [Related]  

  • 76. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Using Disposable Membrane Cell Collector to Enrich Lung Adenocarcinoma Cells in Bloody Pleural Effusion for Anaplastic Lymphoma Kinase Fusion Gene Detection.
    Guo X; Zhao J; Du Y; Liu Y; Ma Y; Wang R; Ji X; Wu J; Dong L
    Acta Cytol; 2021; 65(3):235-241. PubMed ID: 33631757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma.
    Shin SH; Lee H; Jeong BH; Choi YS; Shin MH; Kim S; Han J; Lee KS; Shim YM; Kwon OJ; Kim H
    J Thorac Dis; 2018 Jun; 10(6):3460-3467. PubMed ID: 30069341
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
    Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
    Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
    Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.